Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

Other analysts have also recently issued research reports about the stock. BidaskClub raised shares of Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Needham & Company LLC assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set a “buy” rating and a $30.00 price objective on the stock. Piper Jaffray Companies assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $21.00 price objective on the stock. Barclays PLC assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, William Blair assumed coverage on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday, May 30th. They set an “outperform” rating and a $46.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co has a consensus rating of “Buy” and a consensus price target of $31.75.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) opened at 38.12 on Friday. Biohaven Pharmaceutical Holding Co has a 52 week low of $17.00 and a 52 week high of $38.56. The firm’s market cap is $1.37 billion. The company’s 50-day moving average price is $29.28 and its 200 day moving average price is $25.82.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/10/zacks-investment-research-upgrades-biohaven-pharmaceutical-holding-co-ltd-bhvn-to-hold.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.